Opko Health, Inc. (OPK) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Opko Health’s revenue went from $1.2B in fiscal 2016 to $607M in fiscal 2025, a decline of about 7.5% a year.
Net income in fiscal 2025 was -$226M, a net margin of -37.2%; the best year in this period was 2020 with $31M.
Over the twelve months to September 30, 2026, revenue was $654M and net income -$148M.
Free cash flow was -$191M in fiscal 2025 and positive in 3 of the 10 years shown.
The diluted share count rose 35% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $654M | $607M | $713M | $863M | $1.0B | $1.8B | $1.4B | $902M | $990M | $1.1B | $1.2B |
| Gross profit | $284M | $206M | $219M | $318M | $288M | — | — | — | — | $1.0B | $658M |
| Operating income | -$88M | -$117M | -$152M | -$157M | -$226M | $19M | $58M | -$274M | -$171M | -$276M | -$97M |
| Net income | -$148M | -$226M | -$53M | -$189M | -$328M | -$30M | $31M | -$315M | -$153M | -$305M | -$48M |
| EPS (diluted) | $-0.19 | $-0.30 | $-0.08 | $-0.25 | $-0.46 | $-0.05 | $0.05 | $-0.53 | $-0.27 | $-0.55 | $-0.10 |
| R&D | $128M | $124M | $105M | $90M | $74M | $77M | $75M | $118M | $126M | $126M | $114M |
| Revenue growth | — | −14.9% | −17.4% | −14.0% | −43.4% | +23.6% | +59.2% | −8.9% | −7.2% | −12.6% | +148.4% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$125M | -$179M | -$183M | -$28M | -$95M | $38M | $39M | -$173M | -$109M | -$92M | $32M |
| Capital spending | -$10M | -$12M | -$25M | -$16M | -$25M | -$32M | -$34M | -$13M | -$28M | -$47M | -$19M |
| Free cash flow | -$135M | -$191M | -$208M | -$44M | -$120M | $6M | $6M | -$185M | -$137M | -$139M | $13M |
| Dividends paid | — | — | — | — | — | — | — | — | — | — | — |
| Buybacks | $42M | $47M | $90M | $0 | $0 | — | — | — | — | — | — |
| Stock-based pay | $10M | $11M | $11M | $11M | $19M | $14M | $9M | $13M | $22M | $28M | $43M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $364M | $427M | $96M | $153M | $135M | $72M | $85M | $96M | $91M | $169M |
| Debt | — | $394M | $502M | $77M | $296M | $260M | $290M | $310M | $11M | $13M | $13M |
| Equity | — | $1.3B | $1.4B | $1.4B | $1.6B | $1.7B | $1.7B | $1.6B | $1.8B | $1.8B | $2.0B |
| Total assets | — | $1.9B | $2.2B | $2.0B | $2.2B | $2.4B | $2.5B | $2.3B | $2.5B | $2.6B | $2.8B |
| Shares (diluted) | 746M | 751M | 694M | 752M | 719M | 648M | 641M | 595M | 563M | 559M | 556M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 43.4% | 33.9% | 30.6% | 36.8% | 28.7% | — | — | — | — | 94.3% | 53.8% |
| Operating margin | -13.4% | -19.4% | -21.3% | -18.2% | -22.5% | 1.1% | 4.0% | -30.4% | -17.3% | -25.9% | -7.9% |
| Net margin | -22.6% | -37.2% | -7.5% | -21.9% | -32.7% | -1.7% | 2.1% | -34.9% | -15.4% | -28.6% | -4.0% |
| FCF margin | -20.7% | -31.4% | -29.2% | -5.1% | -11.9% | 0.4% | 0.4% | -20.5% | -13.8% | -13.0% | 1.1% |
| ROIC | — | -6.6% | -6.4% | -8.5% | -10.2% | 0.8% | 1.9% | -11.2% | -7.4% | -11.8% | -3.7% |
| ROE | — | -17.8% | -3.9% | -13.6% | -21.0% | -1.8% | 1.8% | -19.5% | -8.5% | -16.6% | -2.4% |
Frequently asked questions
What is Opko Health’s annual revenue?
$607M in fiscal 2025 and $654M over the twelve months to September 30, 2026.
How much profit does Opko Health make?
Net income was -$226M in fiscal 2025 (net margin -37.2%).
Is Opko Health’s revenue growing?
No: revenue fell 14.9% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.